FXYD5

FXYD domain containing ion transport regulator 5
Identifiers
Symbols	FXYD5 ; HSPC113; IWU-1; IWU1; KCT1; OIT2; PRO6241; RIC; dysad
External IDs	Template:OMIM5 Template:MGI HomoloGene: 7458
Gene ontology Molecular function Template:GNF GO Template:GNF GO Template:GNF GO Cellular component Template:GNF GO Template:GNF GO Biological process Template:GNF GO Template:GNF GO Template:GNF GO
RNA expression pattern
More reference expression data
Orthologs
Template:GNF Ortholog box
Species	Human	Mouse
Entrez	n/a	n/a
Ensembl	n/a	n/a
UniProt	n/a	n/a
RefSeq (mRNA)	n/a	n/a
RefSeq (protein)	n/a	n/a
Location (UCSC)	n/a	n/a
PubMed search	n/a	n/a

FXYD domain containing ion transport regulator 5, also known as FXYD5, is a human gene.

This reference sequence was derived from AF161462.1 and ESTs; validated by multiple replicate ESTs and human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, has not been characterized as a protein. Two transcript variants have been found for this gene, and they are both predicted to encode the same protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu.]

Further reading

• Nam JS, Hirohashi S, Wakefield LM (2007). "Dysadherin: a new player in cancer progression". Cancer Lett. 255 (2): 161–9. doi:10.1016/j.canlet.2007.02.018. PMID 17442482.CS1 maint: Multiple names: authors list (link)
• Adams MD, Kerlavage AR, Fleischmann RD; et al. (1995). "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence". Nature. 377 (6547 Suppl): 3–174. PMID 7566098.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Sweadner KJ, Rael E (2001). "The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression". Genomics. 68 (1): 41–56. doi:10.1006/geno.2000.6274. PMID 10950925.
• Zhang QH, Ye M, Wu XY; et al. (2001). "Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells". Genome Res. 10 (10): 1546–60. PMID 11042152.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Omasa T, Chen YG, Mantalaris A, Wu JH (2001). "A cDNA from human bone marrow encoding a protein exhibiting homology to the ATP1gamma1/PLM/MAT8 family of transmembrane proteins". Biochim. Biophys. Acta. 1517 (2): 307–10. PMID 11342114.CS1 maint: Multiple names: authors list (link)
• Ino Y, Gotoh M, Sakamoto M; et al. (2002). "Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis". Proc. Natl. Acad. Sci. U.S.A. 99 (1): 365–70. doi:10.1073/pnas.012425299. PMID 11756660.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Sato H, Ino Y, Miura A; et al. (2003). "Dysadherin: expression and clinical significance in thyroid carcinoma". J. Clin. Endocrinol. Metab. 88 (9): 4407–12. PMID 12970317.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Clark HF, Gurney AL, Abaya E; et al. (2003). "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMID 12975309.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Shimada Y, Yamasaki S, Hashimoto Y; et al. (2004). "Clinical significance of dysadherin expression in gastric cancer patients". Clin. Cancer Res. 10 (8): 2818–23. PMID 15102690.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Shimada Y, Hashimoto Y, Kan T; et al. (2004). "Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma". Oncology. 67 (1): 73–80. doi:10.1159/000080289. PMID 15459499.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Shimamura T, Yasuda J, Ino Y; et al. (2004). "Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells". Cancer Res. 64 (19): 6989–95. doi:10.1158/0008-5472.CAN-04-1166. PMID 15466191.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Gerhard DS, Wagner L, Feingold EA; et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMID 15489334.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Wu D, Qiao Y, Kristensen GB; et al. (2005). "Prognostic significance of dysadherin expression in cervical squamous cell carcinoma". Pathol. Oncol. Res. 10 (4): 212–8. doi:PAOR.2004.10.4.0212 . PMID 15619642.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Nishizawa A, Nakanishi Y, Yoshimura K; et al. (2005). "Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients". Cancer. 103 (8): 1693–700. doi:10.1002/cncr.20984. PMID 15751018.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Batistatou A, Scopa CD, Ravazoula P; et al. (2006). "Involvement of dysadherin and E-cadherin in the development of testicular tumours". Br. J. Cancer. 93 (12): 1382–7. doi:10.1038/sj.bjc.6602880. PMID 16333245.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Batistatou A, Makrydimas G, Zagorianakou N; et al. (2007). "Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies". Placenta. 28 (5–6): 590–2. doi:10.1016/j.placenta.2006.09.004. PMID 17084448.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Batistatou A, Peschos D, Tsanou H; et al. (2007). "In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin". Br. J. Cancer. 96 (9): 1404–8. doi:10.1038/sj.bjc.6603743. PMID 17437014.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)